FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

University

Drug and asset intelligence for University with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Stage: Development stage unavailable

Recent signals(3)

ClinicalJuly 1, 2026

University of Florida Tests PINPOINT Intervention for Cervical Cancer Prevention

The University of Florida is adapting and testing the PINPOINT intervention to improve cervical cancer prevention among high-risk patients.

ClinicalJune 28, 2026

University of Bern Trials Remote Cognitive Training for Alzheimer's Disease

A study is underway to assess the feasibility and usability of a tablet-based cognitive training program for Alzheimer's disease.

ClinicalJune 22, 2026

University of Edinburgh Investigates Innate Immunity Mechanisms in COPD

The study aims to understand the metabolic dysfunction of immune cells in COPD patients and its impact on bacterial clearance.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Alzheimer's Disease →

Cervical Cancer →

Chronic Obstructive Pulmonary Disease (COPD) →

Therapeutic areas

Alzheimer's Disease →

Cervical Cancer →

Chronic Obstructive Pulmonary Disease (COPD) →

Neurology →

Oncology →

Respiratory →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.